China guideline for liver cancer screening (2022, Beijing) / 临床肝胆病杂志
Jie HE; Wanqing CHEN; Hongbing SHEN; Ni LI; Chunfeng QU; Jufang SHI; Feng SUN; Jing JIANG; Guangwen CAO; Guihua ZHUANG; Ji PENG.
Journal of Clinical Hepatology
; (12): 1739-1772, 2022.
Artículo
en Zh
| WPRIM | ID: wpr-941531
In China, the survival rate of liver cancer remains low while the mortality rate is high. Effectively reducing the burden of liver cancer is still a major challenge in the field of public health and chronic disease prevention in the Chinese population. Optimizing screening strategies for liver cancer remains a profound approach to secondary prevention worthy of continuous exploration. To address this pressing issue, the Bureau of Disease Control and Prevention of the National Health Commission commissioned this guideline. The National Cancer Center of China initiated the guideline development and convened a multidisciplinary expert panel and working groups. Following the World Health Organization Handbook for Guideline Development, this guideline integrated the most up-to-date evidence of liver cancer screening, China's national conditions, and existing practical experience in liver cancer screening. Evidence-based recommendations on the target population, screening technologies, surveillance strategies, and other key points across the process of liver cancer screening and surveillance management were provided. This guideline would help standardize the practice of liver cancer screening in China.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados